Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Freiburg im Breisgau, Germany Clinical Trials

A listing of Freiburg im Breisgau, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (7) clinical trials

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

The aim of the study is to determine a recommended dose for F16IL2 in combination with BI 836858 in AML relapse after alloHSCT and investigating safety and tolerability of the combination regimen. Dose escalation will be guided by a Bayesian logistic regression model (BLRM) with overdose control that will be ...

Phase

0.0 miles

Learn More »

Safety Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis

The drug being tested in this study is called ixazomib. Ixazomib is being tested to find a safe and well tolerated dose in participants with lupus nephritis. This study will look at side effects and lab results in participants who take ixazomib, along with the determination of the pharmacokinetics (PK). ...

Phase

0.0 miles

Learn More »

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of INCMGA00012 administered IV every 2, 3, or 4 weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors. In the initial ...

Phase

0.43 miles

Learn More »

Phase 1 Trial of MSC2490484A an Inhibitor of a DNA-dependent Protein Kinase in Combination With Radiotherapy

MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

Phase

0.43 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

0.43 miles

Learn More »

A Safety Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase and an expansion phase.

Phase

0.43 miles

Learn More »

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

Phase

0.43 miles

Learn More »